#
Before
Extended Answer
The Hulscher et al. study published in Anticancer Research (June 2026) has generated significant online attention, but its scientific and ethical context demands careful scrutiny before any clinical Reliability** was an observational, retrospective study. Self-reported benefit rates — however striking — cannot establish causation or efficacy without controlled comparison groups.
- What does the journal’s Expression of Concern mean? On June 1, 2026, the journal issued a formal Expression of Concern citing unresolved questions about data verifiability, statistical reliability, and ethical oversight. This is a significant red flag warranting caution.
- Were outcomes objectively measured? The 84.4% “clinical benefit” rate was self-reported by patients, introducing substantial recall and selection bias.
About Conflicts of Interest
- Who funded and conducted this research? All 12 authors are affiliated with and/or compensated by The Wellness Company (TWC) and/or the McCullough Foundation — and TWC is the sole commercial seller of the specific compounded ivermectin-mebendazole product studied. Understanding how conflicts of interest affect oncology research integrity is essential context for interpreting these findings.
- Does financial interest in the product affect the reliability of the findings? Patients deserve a frank conversation about how undisclosed or inadequately managed conflicts can distort study conclusions. Asking your oncologist targeted questions about alternative cancer therapies is one of the most effective ways to cut through noise and get grounded clinical perspective.
About the Broader Scientific Landscape
- Is there independent research on ivermectin in cancer? The National Cancer Institute has conducted separate, unrelated preclinical laboratory research into ivermectin’s potential mechanisms — but preclinical findings do not translate directly to patient benefit. To understand the full scope of what science currently shows, it helps to review what the evidence actually says about ivermectin as a cancer treatment.
- Are any rigorous human trials underway? One actively registered trial (NCT05318469) is evaluating ivermectin combined with checkpoint inhibitors in metastatic triple-negative breast cancer. Patients and clinicians should verify the current status and any interim results of NCT05318469 directly at ClinicalTrials.gov before drawing conclusions.
- What are the known risks of off-label ivermectin use? Dosing outside approved parameters carries real toxicity risks, particularly in patients undergoing concurrent chemotherapy or immunotherapy. Understanding what ivermectin is actually approved to treat helps clarify the significant gap between its licensed uses and experimental cancer applications.
About Your Specific Situation
- How would off-label ivermectin interact with my current treatment regimen?
- What is the evidence threshold your institution uses before recommending off-label agents?
- Could participation in a registered clinical trial offer access to investigational agents with appropriate oversight?
Knowing how to evaluate cancer treatment claims is foundational before patients or providers act on viral study claims.
Related Questions
Q: What does the journal’s Expression of Concern about this study actually mean for patients?
An Expression of Concern signals that the journal has identified serious unresolved questions — about data integrity, methodology, or ethical oversight — that have not yet been corrected or retracted. It does not confirm fraud, but it preclinical research investigates biological mechanisms in laboratory settings; it does not evaluate compounded ivermectin-mebendazole products in human patients and should not be cited as support for clinical use. For a detailed breakdown of [what the Hulscher et al. 2026 study actually found and context is essential before drawing any comparisons.
Q: What is the current status of the ivermectin breast cancer trial (NCT05318469)?
NCT05318469 is a registered human oncology trial evaluating ivermectin with checkpoint inhibitors in metastatic triple-negative breast cancer. Its current enrollment status, interim findings, and completion timeline should be verified independently at ClinicalTrials.gov, as trial statuses change frequently. For broader context on how drugs like ivermectin enter the oncology pipeline, see what drug repurposing means and whether ivermectin could ever play a role in cancer care.
Sood Laboratory (ASL) as an Educational Resource
Sood Laboratory (ASL) is committed to helping cancer patients and caregivers navigate complex, often contradictory information about emerging and unproven treatments. Our educational resources are designed to support — not replace — conversations with your oncology team. If you have questions about evaluating research claims, understanding clinical trial design, or distinguishing preclinical findings from clinical evidence, finding trustworthy information about experimental treatments is a skill ASL’s resources are designed to help build — grounded in scientific integrity and patient advocacy.
Additional Related Articles
📖 How to Evaluate Conflicts of Interest in Cancer Research — Explains why author affiliations and commercial funding sources are critical context when interpreting oncology study findings.
📖 [Understanding Observational Studies vs. Randomized Controlled Trials in